Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 1936 (LINC01936) is a long non-coding RNA located at chromosome 2p23.1, primarily expressed in the lung, heart, and thyroid[1][2][5]. It is significantly downregulated in lung squamous cell carcinoma (LUSC) and lung adenocarcinoma, where it functions as a tumor suppressor. Overexpression of LINC01936 reduces proliferation, migration, and invasion of LUSC cells while promoting apoptosis. Mechanistically, LINC01936 is involved in deactivation of epithelial-mesenchymal transition (EMT), regulation of immune cell infiltration, inhibition of angiogenesis, and modulation of cell adhesion and extracellular matrix-interactions. Its lower expression correlates with worse prognosis in lung cancer, making it a potential prognostic biomarker and a putative therapeutic target for lung cancers. Currently, there are no known drugs or direct targeting modalities for LINC01936, and its therapeutic application remains investigational[1][2][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 1936 (LINC01936).